Ivabradine is an approved therapy to reduce hospitalizations in a specific subset of patients with symptomatic heart failure, reduced ejection fraction, and persistently elevated heart rate.
Does ivabradine reduce hospitalizations in patients with symptomatic heart failure, reduced ejection fraction, and persistently elevated heart rate despite otherwise maximal medical therapy?
This review summarizes the clinical evidence for ivabradine in patients with HFrEF and elevated heart rate, placing it within the current multifaceted treatment scheme.
Ivabradine is approved to reduce hospitalizations for patients with symptomatic heart failure, reduced ejection fraction, and persistently elevated heart rate despite otherwise maximal medical therapy. However, the eligible patient population is a small fraction of those with heart failure overall. This review summarizes the major clinical evidence supporting the use of ivabradine, identifies and discusses areas of uncertainty from the clinical trial data, helps describe the population most likely to benefit, and attempts to place ivabradine within the multifaceted treatment scheme currently used for patients with heart failure and reduced ejection fraction.
Psotka et al. (Tue,) conducted a review in Heart failure with reduced ejection fraction. Ivabradine was evaluated. Ivabradine is an approved therapy to reduce hospitalizations in a specific subset of patients with symptomatic heart failure, reduced ejection fraction, and persistently elevated heart rate.